- Poster presentation
- Open Access
Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade
© Monjazeb et al; licensee BioMed Central Ltd. 2013
- Published: 7 November 2013
- Tumor Bear Mouse
- Drain Lymph Node
- Treatment Related Toxicity
- Center Testing
- Robust Response
Pre-clinical and clinical data demonstrate the effectiveness of combining RT and CpG immunotherapy. There is data to suggest that the effectiveness of CpG immunotherapy may be limited by induction of the immunosuppressive enzyme, IDO. We test the efficacy and safety of combining RT and CpG with blockade of the immunosuppressive enzyme, IDO, using 1-Methyl D-Tryptophan (1-MT).
Tumor bearing mice were treated with RT + IT. IT consisted of intratumoral CpG and 1-MT administered in the drinking water. Tumor growth, survival, toxicity and the immune profile of various tissues were assessed. Based on preliminary results a similar clinical trial was initiated at the UC Davis Veterinary Cancer Center testing this approach for spontaneous metastatic cancers in companion canines.
In mice therapy improved overall survival, decreased lung metastases, decreased mean tumor growth, increased percentage of activated dendritic cells in tumor draining lymph nodes, and decreased levels of regulatory T-cells. No treatment related toxicities were observed.
In the canine clinical trial 6 patients have been enrolled to date. No treatment related toxicities have been observed. Preliminary results indicate a robust response at the primary treated disease site but also indicate the induction of systemic anti-tumor immunity as demonstrated by regression or stability of un-irradiated metastatic disease. The treatment has drastically reduced the level of regulatory T-cells in the tumor, draining lymph nodes, and peripheral blood in some animals.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.